Viridian Therapeutics Inc 2026年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF1934 For the transition period fromtoCommission File No.001-36483 VIRIDIAN THERAPEUTICS, INC. 02453(Zip Code) (Former name, former address and former fiscal year, if changed since last report):N/ASecurities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90days.Yes☒No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that theregistrant was required to submit such files).Yes☒No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of May1, 2026, there were 103,074,740 shares of the registrant’s common stock outstanding. VIRIDIAN THERAPEUTICS, INC.INDEX PART I. FINANCIAL INFORMATIONItem1. Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets7Condensed Consolidated Statements of Operations and Comprehensive Loss8Condensed Consolidated Statements of Changes in Stockholders’ Equity9Condensed Consolidated Statements of Cash Flows10Notes to Unaudited Condensed Consolidated Financial Statements11Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item3. Quantitative and Qualitative Disclosures about Market Risk37Item4. Controls and Procedures38 Item1. Legal Proceedings38Item1A. Risk Factors38Item2. Unregistered Sales of Equity Securities and Use of Proceeds80Item3. Defaults Upon Senior Securities80Item4. Mine Safety Disclosures80Item5. Other Information80Item6. Exhibits80 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements that involve risks and uncertainties.The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”“possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-lookingstatements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statementscontained in this Quarterly Report include, but are not limited to, statements about: •the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other results;•the potential utility, efficacy, potency, safety, clinical benefits, half-life, clinical response, convenience and number ofindications of our product candidates;•the timing and focus of our ongoing and future nonclinical studies and clinical trials and the timing of reporting data fromthose studies and trials, including data from our REVEAL-2 phase 3 clinical trial of elegrobart in patients with active thyroideye disease (“TED”) expected in the second quarter of 2026, and data from our phase 1 clinical trial of VRDN-008 in healthyvolunteers expected in the second half of 2026;•the timing or likelihood of regulatory filings and approvals, including the potential approval of the biologics licenseapplication (“BLA”) for veligrotug, which is under Priority Review by the U.S. Food and Drug Administration (“FDA”), andsubmission of the Marketing Authorization Application (“MAA”) for veligrotug submitted to the European MedicinesAgency (“EMA”) in January 2026, our potential submission of an investigational new drug application (“IND”) for our anti-thyroid stimulating hormone receptor (“TSHR”) candidate in the fourth quarter of 2026, and our potential submission of aBLA for elegrobart in the first quarter of 2027;•our plans relating to the further development of our product candidates, including additional indica